NBC Securities’s Adverum Biotechnologies ADVM Stock Holding History

NBC Securities’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50	Closed	–	–	2107
2023 Q3	$0	Buy	+50	New	+$898	﹤0.01%	2105

Other funds holding ADVM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

NBC Securities's ADVM Position: Q4 2023 in Review

NBC Securities sold out of Adverum Biotechnologies (ADVM) in Q4 2023, closing a stake of 50 shares.

NBC Securities first reported a position in ADVM in Q3 2023 and held it in 1 quarter. The position peaked at $0 in Q3 2023. 60 funds tracked by Wall St. Rank hold ADVM as of Q4 2023.

NBC Securities reported no remaining Adverum Biotechnologies position as of Q4 2023 after selling out during the quarter.
NBC Securities sold 50 Adverum Biotechnologies shares in Q4 2023.
NBC Securities first reported a position in Adverum Biotechnologies in Q3 2023 and held it in 1 quarter.
NBC Securities's Adverum Biotechnologies position peaked at $0 in Q3 2023.
60 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2023.

Based on NBC Securities's 13F filing for Q4 2023, filed 7 Feb 2024.